Abstract
PM Pitrez, RG de Souza, C Roncada. Pediatr Pulmonol. 2017;52(11):1408–1413 In this study, the authors examined the health care effects associated with the use of omalizumab for severe childhood asthma in low- and middle-income countries (LMICs). This retrospective chart review included 6- through 12-year-olds who were managed at a tertiary referral center in Brazil with a confirmed diagnosis of severe therapy-resistant asthma (STRA) on the basis of European Respiratory Society/American Thoracic Society criteria, including requiring treatment with inhaled corticosteroids (ICSs) with long-acting β2 agonists and leukotriene modifier …
Full Text
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call